Long Noncoding RNA CYP4A22-AS1 Drives Radioresistance in Cervical Adenocarcinoma

Cervical adenocarcinoma often resists radiotherapy, and the reasons have remained poorly understood. A new study published in Molecular Cancer identifies a long noncoding RNA, CYP4A22-AS1, as a consistent driver of this intrinsic resistance, linking metabolic adaptation to DNA damage repair through a defined molecular pathway.

The researchers integrated transcriptomic analyses of TCGA data with an independent RNA-sequencing cohort to find dysregulated long noncoding RNAs in cervical adenocarcinoma. CYP4A22-AS1 emerged as consistently upregulated in the disease, and elevated levels were associated with aggressive clinicopathological features and poor clinical outcome.

Mechanistically, the team showed that CYP4A22-AS1 directly interacts with YBX1, a protein that binds both RNA and DNA. This interaction promotes YBX1’s accumulation in the cell nucleus and enhances its recruitment to the promoter of PGK1, a gene encoding a glycolytic enzyme, resulting in transcriptional activation of PGK1. In other words, the RNA acts as a molecular chaperone that steers a transcriptional regulator toward a metabolic gene.

The functional consequences were tested with a broad set of experiments, including clonogenic survival, proliferation and apoptosis assays, measurements of glycolytic flux, xenograft irradiation models, patient-derived organoids, and clinical validation, supported by RNA pull-down, RNA immunoprecipitation, chromatin immunoprecipitation, immunofluorescence, and rescue experiments. Disrupting the CYP4A22-AS1–YBX1–PGK1 axis suppressed glycolytic activity, impaired DNA damage repair, increased radiation-induced apoptosis, and markedly enhanced radiosensitivity in vitro.

The findings held up in living models. CYP4A22-AS1 promoted resistance to irradiation in xenograft and patient-derived organoid models, and clinically, elevated expression of both CYP4A22-AS1 and PGK1 correlated with unfavorable prognosis.

The authors conclude that the pathway represents a potential therapeutic vulnerability for improving radiotherapy response in cervical adenocarcinoma. Because the work is preclinical and its clinical correlations are associative, translating the axis into a treatment target will require further validation, but the study offers a previously unrecognized, RNA-dependent mechanism coupling metabolism to radiation survival in this cancer type.

Subject of Research: A long noncoding RNA mechanism linking glycolysis and DNA damage repair to radioresistance in cervical adenocarcinoma

Article Title: CYP4A22-AS1 controls YBX1 nuclear accumulation to promote metabolic adaptation and radioresistance in cervical adenocarcinoma

Article References: Zhou, M., Gao, Y., Zhang, Y., He, L., Wang, C., Zhang, Y., Li, C., Anfossi, S., Claret, F. X., Calin, G. A., & Wang, D. (2026). CYP4A22-AS1 controls YBX1 nuclear accumulation to promote metabolic adaptation and radioresistance in cervical adenocarcinoma. Molecular Cancer. https://doi.org/10.1186/s12943-026-02816-1

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02816-1

Keywords: CYP4A22-AS1, long noncoding RNA, YBX1, PGK1, cervical adenocarcinoma, radioresistance, glycolysis, DNA damage repair, radiosensitivity, patient-derived organoids, Molecular Cancer, controls